GHRH receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-30. Numbers and descriptions here follow the published literature rather than marketing material.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Located on pituitary somatotroph cells |
| Signaling route | cAMP–protein kinase A | Gs-coupled receptor pathway |
| Downstream markers | Growth hormone and IGF-1 | Used as pharmacodynamic readouts |
| Common detection | LC-MS/MS | Separates intact peptide from fragments |
| Typical storage | 2–8 °C, protected from light | Applies to solid form before reconstitution |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
=== Cultural === Cultural attitudes towards body image, beauty, and health also significantly impact the incidence of anorexia nervosa. There is a stark contrast between Western societies that idolize slimness and certain Eastern traditions that worship gods depicted with larger bodies, and these varying cultural norms have varying influences on eating behaviors, self-perception, and anorexia in their respective cultures. For example, despite the fact that "fat phobia", or a fear of fat, is a key diagnostic criteria of anorexia by the DSM-5, anorexic patients in Asia rarely display this trait, as deep-rooted cultural values in Asian cultures praise larger bodies. Fat phobia appears to be intricately linked to Western culture, encompassing how various cultural perceptions impact anorexia in various ways. It calls on the need for greater, diverse cultural consideration when looking at the diagnosis and experience of anorexia. For instance, in a cross-sectional study done on British South Asian adolescent English adolescent anorexia patients, it was found that both patients' symptom profiles differed. South Asians were less likely to exhibit fat-phobia as a symptom versus their English counterparts, instead exhibiting loss of appetite. Patients usually attributed their restricted food intake to somatic symptoms such as bloating, stomach pain, or lack of appetite. However, both kinds of patients had distorted body images, implying the possibility of disordered eating and highlighting the need for cultural sensitivity when diagnosing anorexia.
Before the arrival of viticulture, Ningxia's 6.8 million people, 36 per cent of whom are Muslims from the Hui ethnic group, relied largely on animal grazing, subsistence agriculture and the cultivation of wolfberries used in traditional Chinese medicine. Since then, winemaking has become the premier specialty of Ningxia, and the province devotes almost 40,000 hectares to vineyards and producing 120 million bottles of wine in 2017 – a quarter of the entire nation's production.
== Structure and bonding == Thiols having the structure R−S−H, in which an alkyl group (R) is attached to a sulfhydryl group (SH), are referred to as alkanethiols or alkyl thiols. Thiols and alcohols have similar connectivity. Because sulfur atoms are larger than oxygen atoms, C−S bond lengths—typically around 180 picometres—are about 40 picometers longer than typical C−O bonds. C−S−H angles approach 90°, whereas the angle for the C−O−H group is more obtuse. In solids and liquids, the hydrogen-bonding between individual thiol groups is weak, and thus thiols are more volatile than the corresponding alcohols. The main cohesive forces for thiols involves Van der Waals interactions between the highly polarizable divalent sulfur centers. The S−H bond is much weaker than the O−H bond as reflected in their respective bond dissociation energies (BDE). For CH3S−H, the BDE is 366 kJ/mol (87 kcal/mol), while for CH3O−H, the BDE is 440 kJ/mol (110 kcal/mol). Hydrogen-atom abstraction from a thiol gives a thiyl radical with the formula RS•, where R = alkyl or aryl.
==== ADHD ==== Long-term amphetamine exposure at sufficiently high doses in some animal species is known to produce abnormal dopamine system development or nerve damage, but, in humans with ADHD, long-term use of pharmaceutical amphetamines at therapeutic doses appears to improve brain development and nerve growth. Reviews of magnetic resonance imaging (MRI) studies suggest that long-term treatment with amphetamine decreases abnormalities in brain structure and function found in subjects with ADHD, and improves function in several parts of the brain, such as the right caudate nucleus of the basal ganglia. Reviews of clinical stimulant research have established the safety and effectiveness of long-term continuous amphetamine use for the treatment of ADHD. Randomized controlled trials of continuous stimulant therapy for the treatment of ADHD spanning 2 years have demonstrated treatment effectiveness and safety. Two reviews have indicated that long-term continuous stimulant therapy for ADHD is effective for reducing the core symptoms of ADHD (i.e., hyperactivity, inattention, and impulsivity), enhancing quality of life and academic achievement, and producing improvements in a large number of functional outcomes across 9 categories of outcomes related to academics, antisocial behavior, driving, non-medicinal drug use, obesity, occupation, self-esteem, service use (i.e., academic, occupational, health, financial, and legal services), and social function.
=== Coupling of ECD with separation techniques === ECD has been coupled with capillary electrophoresis (CE) to gain insight into structural analysis of mixture of peptides and protein digest. Micro-HPLC combined with ECD FTICR was used to analyze pepsin digest of cytochrome c. Sequence tags were provided by analysis of a mixture of peptides and tryptic digest of bovine serum albumin when LC ECD FTICR MS was used. Additionally, LC-ECD-MS/MS is provides longer sequence tags than LC-CID-MS/MS for identification of proteins. ECD devices using radio frequency quadrupole ion trap are relevant for high-throughput proteomics. Recently, Atmospheric pressure electron capture dissociation (AP-ECD) is emerging as a better technique because it can be implemented as a stand-alone ion-source device and doesn't require any modification of the main instrument.
Sources: en.wikipedia.org
The oxygen transmission rate of a gas through packaging is defined as the amount of oxygen permeating per unit of permeable area and per unit of time in a packaging system considering standardized test conditions (23 °C and 1 atm. partial pressure difference). It is an effective tool to estimate the barrier properties of a certain material. The determination of the OTR is usually carried out by means of a steady-state and isostatic method, reported by the ASTM D 3985 or ASTM F 1307, containing respectively standardized protocols for the measurements of the OTR of several kinds of packaging. The typical instrumentation consists in a permeation cell composed by two distinct chambers, separated by the tested material; one of the chambers is then filled with a carrier gas (e.g., nitrogen), while the other one with oxygen, hence creating the necessary driving force to let the oxygen permeate across the barrier's material.
India's population was 361 million in 1951. It grew to approximately 1.464 billion in 2025, surpassing China's population in 2021. 1,210,193,422 residents were reported in the 2011 provisional census report. The median age was 28.7 in 2020. Medical advances made in the last 50 years as well as increased agricultural productivity brought about by the "Green Revolution" have caused India's population to grow rapidly, though India's decennial rates of growth are decreasing: its population grew by 17.64% from 2001 to 2011, compared to 21.54% growth in the previous decade (1991–2001). The first post-colonial census, conducted in 1951, counted 361 million people. The life expectancy at birth has increased from 49.7 years in 1970–1975 to 72.0 years in 2023. The under-five mortality rate for the country was 113 per 1,000 live births in 1994, and had declined to 41.1 per 1,000 live births by 2018. The 2011 census reported a human sex ratio of 940 females per 1,000 males. Female infanticide in India, and lately female foeticide, have created lopsided gender ratios; the number of missing women in the country quadrupled from 15 million to 63 million during the period 1964–2014, faster than the population growth during the same period. According to an Indian government study, an additional 21 million girls are unwanted and do not receive adequate care. Despite a government ban on sex-selective foeticide, the practice persists. Migration from rural to urban areas has been an important dynamic in India's recent history.
=== Study of human emotions === At the beginning of her career, Barrett's research focused on the structure of affect, having developed experience-sampling methods and open-source software to study emotional experience. Barrett and members at the Interdisciplinary Affective Science Laboratory study the nature of how the brain creates the mind broadly from social-psychological, psychophysiological, cognitive science, and neuroscience perspectives, and take inspiration from anthropology, philosophy, and linguistics. They also explore the relationship between emotion and vision and other psychological phenomena. In 2010, she joined the psychology faculty at Northeastern University. Before that, she held academic positions at Boston College (1996-2010) and was an assistant professor of clinical psychology at Pennsylvania State University. Notable doctoral students of Barrett's include Tamlin Conner. Her research has focused on the main issues in the science of emotions such as:
== Mechanism of action == Phalloidin binds F-actin, preventing its depolymerization and poisoning the cell. Phalloidin binds specifically at the interface between F-actin subunits, locking adjacent subunits together. Phalloidin, a bicyclic heptapeptide, binds to actin filaments much more tightly than to actin monomers, leading to a decrease in the rate constant for the dissociation of actin subunits from filament ends, which essentially stabilizes actin filaments through the prevention of filament depolymerization. Moreover, phalloidin is found to inhibit the ATP hydrolysis activity of F-actin. Thus, phalloidin traps actin monomers in a conformation distinct from G-actin and it stabilizes the structure of F-actin by greatly reducing the rate constant for monomer dissociation, an event associated with the trapping of ADP. Overall, phalloidin is found to react stoichiometrically with actin, strongly promote actin polymerization, and stabilize actin polymers. Phalloidin functions differently at various concentrations in cells. When introduced into the cytoplasm at low concentrations, phalloidin recruits the less polymerized forms of cytoplasmic actin as well as filamin into stable "islands" of aggregated actin polymers, yet it does not interfere with stress fibers, i.e. thick bundles of microfilaments. Wehland et al. also notes that at higher concentrations, phalloidin induces cellular contraction.
== Development == Zhonghua Fu runs a clinic in Nanjing, China, affiliated with Nanjing University of Chinese Medicine. At the FSN clinic for pain medicine, FSN is used as the sole means to treat musculoskeletal disorders and some chronic benign visceral disorders. Fu originally trained as a TCM doctor, completing his masters in acupuncture. While practicing and teaching traditional acupuncture in Guangzhou, he realized that several innovations were needed to improve and accelerate the acupuncture effect. Because some techniques for painful problems in the ancient Huangdi Neijing were punctured obliquely surrounding some painful spots, Fu thought inserting horizontally was a good choice, and then FSN came into being after a number of trials. After completing his Ph.D., Fu conducted research in his lab for two years on arthritic rats. During these trials, when the needle was inserted into the local point of sensitivity, there were no profound changes in VAS and range of motion. Notable changes in VAS and range of motion were observed however when the needle was inserted parallel to the skin surface.
Sources: en.wikipedia.org
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.
IGF-1 reflects growth hormone activity but changes slowly and can be measured from one sample. Growth hormone itself is pulsatile, which makes single measurements hard to interpret.
The receptor pathway is well described, but how individual responses vary and what governs long-term outcomes remain open questions. Reported differences across studies are often attributed to assay and population factors.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.